(Q41133348)

27 September 2017

title

Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status (English)

1 reference

27 September 2017

1 reference

9

Steven A Narod

1 reference

27 September 2017

Joanne Kotsopoulos

1

1 reference

27 September 2017

Barry Rosen

2

1 reference

27 September 2017

Isabel Fan

3

1 reference

27 September 2017

Joel Moody

4

1 reference

27 September 2017

John R McLaughlin

5

1 reference

27 September 2017

Harvey Risch

6

1 reference

27 September 2017

Taymaa May

7

1 reference

27 September 2017

Ping Sun

8

1 reference

27 September 2017

language of work or name

English

0 references

publication date

7 November 2015

1 reference

27 September 2017

1 reference

27 September 2017

volume

140

1 reference

27 September 2017

issue

1

1 reference

27 September 2017

page(s)

42-47

1 reference

Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2

27 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

Why have ovarian cancer mortality rates declined? Part II. Case-fatality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

Why have ovarian cancer mortality rates declined? Part III. Prospects for the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

Improved survival in women with BRCA-associated ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

Five year survival rates can mislead

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

The relationship between the roles of BRCA genes in DNA repair and cancer predisposition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

Aggressive surgical effort and improved survival in advanced-stage ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

Differences in tumor type in low-stage versus high-stage ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.009

10.1016/J.YGYNO.2015.11.009

7 January 2021

Identifiers

DOI

1 reference

27 September 2017

1 reference